The iconic rise of Viagra has long been a benchmark of pharmaceutical success, but its position within the broader sector now presents questions about long-term yields . Copycat versions are diminishing exclusivity , prompting worries that investing in companies closely tied to Viagra's once-dominant position could be a dangerous decision , especia